TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03351205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dried biological amnion graft
Description: Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dried biological amnion graft
Description: Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate tablets+dydrogesterone tablets
Description: oral estradiol valerate tablets+dydrogesterone tablets
Study: NCT03643536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-WPEP
Description: The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-WPEP
Description: The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
Study: NCT01809470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FIFA2013
Description: Playing FIFA2013 for 1 hour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Call of Duty
Description: Playing Call of Duty for 1 hour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching TV
Description: Watching TV for 1 hour
Study: NCT02069002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied relaxation group therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information session (psychoeducation)
Study: NCT02837679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Follow up
Study: NCT04790591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Same-day surgery
Description: To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Same-day surgery
Description: To be allowed same-day discharge certain postoperative criteria have to be met. These are categorized into four dimensions - vital parameters, urinary function, bleeding, and mobilization.
Study: NCT00768898

Intervention type: OTHER
Intervention: 2.5/5.0/10.0 ÂµL lissamine green
Description: vital stain solution

Intervention type: OTHER
Intervention: 2.5/5.0/10.0 ÂµL lissamine green
Description: vital stain solution

Intervention type: OTHER
Intervention: 2.5/5.0/10.0 ÂµL lissamine green
Description: vital stain solution
Study: NCT00962273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive computerized learning resource
Description: In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Didactic computerized learning resource
Description: In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
Study: NCT02949128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight: ≥ 40 to \< 60 kilograms (kg), 2400 milligrams (mg) loading, then 3000 mg every 8 weeks; ≥ 60 to \< 100 kg, 2700 mg loading, then 3300 mg every 8 weeks; ≥ 100 kg, 3000 mg loading, then 3600 mg every 8 weeks.
Study: NCT00783016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Morphine
Study: NCT02469805

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Shepherd catheter
Description: Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
Study: NCT02625077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastroesophageal valvuloplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Toupet fundoplication
Study: NCT02223741

Intervention type: OTHER
Intervention: Korean medical treatment
Description: acupuncture and herbal drugs
Study: NCT00416520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Another phosphate binder (Sevelamer)
Description: Current approved dosing recommendations for 12 weeks
Study: NCT02821247

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Intravitreal injection; should comply with the recommendations written in the local Summary of Product Characteristics (SPC) of the product
Study: NCT00680836

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally two times per day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: 550 mg orally two times per day for 14 days
Study: NCT02487992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Killer Cells
Description: CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
Study: NCT03972631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle education
Description: Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle education
Description: Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Description: One to one intensive lifestyle intervention according to the diet and activity plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric low-carbohydrate diet plan
Description: A diet plan with restricted calorie and carbohydrate intake
Study: NCT01903265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL 2.8mg
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Study: NCT02913248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional periodontal treatment
Description: Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
Study: NCT03018132

Intervention type: OTHER
Group type: OTHER
Intervention: mental health screening, education and referral program
Description: I. Psychosocial assessments:~1. Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~2. Exercise, smoking \& substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~1. All receive a brochure entitled, Speak Up When You Are Down~2. If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~3. Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral.
Study: NCT00483327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Study: NCT04323371

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: Blood and derived fluids will be collected from 26 ADHF CS patients admitted to intensive care at Niguarda Hospital and locally stored.Stocked samples will be shipped to the Central Laboratories at Milano Uni and MilaIFC-CNR for the metabolomic and biomarkers analysis,respectively.To evaluate interleukin-6 (marker of systemic inflammation),angiopoietin-2 (marker of endothelial permeability), syndecan-1 and heparan sulfate (markers of endothelial glycocalyx),2 aliquotes of serum samples will be used by IFC CNR.The biomarkers will be assessed through ELISA analytical techniques, based on the interactions inside a microplate between a primary pre-coated antibody and the specific protein contained in serum samples.A secondary antibody, link to a horseradish peroxidase (HRP) detection system, is able to recognize and bind the antigen, and to produce a colorimetric reaction after the addition of enzyme substrate which is proportional to the amount of the target protein bound
Study: NCT03198143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
Study: NCT03156803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy eating blog
Description: For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
Study: NCT03266835

Intervention type: DEVICE
Group type: OTHER
Intervention: SoundBite™ Crossing System - Peripheral
Description: SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
Study: NCT00176293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: oral dexamethasone, 12mg BID on days 1, 2, 3, 4, \& 5 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin 50mg/m\^2 I.V. on day 5
Study: NCT01322022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ParentTraining
Description: 5 sessions of individual parent training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: Parent Education to control for time and attention
Study: NCT03195517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Study: NCT03325322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Flavonoid family

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT04724161

Intervention type: DIAGNOSTIC_TEST
Intervention: ANC surveillance
Description: Clinic-based testing of all pregnant women during antenatal care visits using national standards and commercially available malaria rapid diagnostic tests
Study: NCT00657384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acid tranexamic
Description: 10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nacl 0.9%
Description: 10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
Study: NCT02863341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Team-care deprescribing with deprescribing guide
Description: Beers criteria 2015, STOPP criteria 2014, drug interaction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Team-care deprescribing with deprescribing guide
Description: Beers criteria 2015, STOPP criteria 2014, drug interaction
Study: NCT01327755

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Selenium yeast containing selenomethionine 200 mcg per day for 2 years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same number of pills, frequency, and duration as selenium intervention.
Study: NCT00804687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39220675
Description: Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39220675
Description: Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
Study: NCT02962934

Intervention type: OTHER
Intervention: Non CRRT group
Description: Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.

Intervention type: OTHER
Intervention: CRRT group
Description: CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.~Ultrafiltrate samples at 1 hr,2h 4h 6h 8h
Study: NCT01182415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: Autologous stem cell transplant following high-dose chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Description: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
Study: NCT02975141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 30Mg Tab
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 30Mg Tab
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 30Mg Tab
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib 40Mg Tab
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Chemotherapy Backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Chemotherapy Backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Chemotherapy Backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Chemotherapy Backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Chemotherapy Backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Chemotherapy Backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Chemotherapy Backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Chemotherapy Backbone
Study: NCT02685462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Study: NCT01846845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Prosthetic Transfemoral Socket System
Description: Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Prosthetic transfemoral socket system
Description: Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
Study: NCT04005859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 2. Liposomal bupivacaine TAP block (experimental arm)~1. Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.~2. A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.~3. The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.~4. Adhesive tapes will be applied at the level of the TAP block puncture sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Lidocaine
Description: 1. Intravenous Lidocaine infusion (control arm, current standard of care)~1. 100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.~2. 1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.~3. Adhesive tapes will be applied at the presumed level of TAP block puncture sites.
Study: NCT01974297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg, fenofibric acid 135mg
Description: Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 20mg
Description: Atorvastatin 20mg/day PO for 12weeks
Study: NCT03168633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based DM2 information pages
Description: Each email will include information on one of the following topics:~1. The importance of physical activity~2. Correct nutrition~3. The importance of adhering to medication regimens.~Emails will be either positive (e.g., the importance of good nutrition, and what constitutes good nutrition) or negative (e.g., the risks of not adhering to medications).~The information will be provided by different approaches: medical research results, practical tips, patient testimonies....
Study: NCT00864591

Intervention type: PROCEDURE
Intervention: SPECT Imaging
Description: Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.

Intervention type: PROCEDURE
Intervention: Stress Adenosine CMR
Description: CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography.